Shiga toxin-producing escherichia coli

Pathogenic Escherichia coli in Latin America

Volumn , Issue , 2010, Pages 65-83

  Guth, Beatriz E C ^a   Prado, Valeria ^b   Rivas, Marta ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CHILE   (Chile)

^c INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875606068     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/978160805192211001010065     Document Type: Chapter

References (204)

1. Konowalchuk J, Speirs JI, Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect Immun. 1977;18:775-779.
2. O'Brien AD, LaVeck GD, Thompson MR, et al. Production of Shigella dysenteriae type 1-like cytotoxin by Escherichia coli. J Infect Dis. 1982;146:763-769.
3. Melton-Celsa A, O'Brien AD. Structure, biology, and relative toxicity of Shiga toxin family members for cells and animals. In: Kaper JB, O'Brien AD (eds), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. ASM Press. Washington, DC. 1998;pp121-128.
4. Riley LW, Remis RS, Helgerson SD, et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med. 1983;308:681-685.
5. O'Brien AD, Lively TA, Chen ME, et al. Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (Shiga) like cytotoxin. Lancet. 1983;i:702.
6. Johnson WM, Lior H, Bezanson. Cytotoxic Escherichia coli O157:H7 associated with haemorrhagic colitis in Canada. Lancet. 1983;i:76.
7. Levine MM, Xu J, Kaper JB, et al. A DNA probe to identify enterohemorrhagic Escherichia coli of O157:H7 and other serotypes that cause hemorrhagic colitis and hemolytic uremic syndrome. J Infect Dis. 1987;156:175-182.
8. Karmali MA, Petric M, Lim C, Fleming et al. The association between hemolytic uremic syndrome and infection by Verotoxin-producing Escherichia coli. J Infect Dis. 1985;151:775-782.
9. Karmali MA, Steele BT, Petric M, et al. Sporadic cases of hemolytic uremic syndrome associated with fecal cytotoxin and cytotoxin producing Escherichia coli. Lancet. 1983;i:619-620.
10. Paton AW, Woodrow MC, Doyle RM, et al. Molecular characterization of a Shiga toxigenic Escherichia coli O113:H21 strain lacking eae responsible for a cluster of cases of hemolytic-uremic syndrome. J Clin Microbiol. 1999;37:3357-3361.
11. Abaas S, Franklin A, Kuhn I, et al. Cytotoxin activity on Vero cells among Escherichia coli strains associated with diarrhea in cats. Am J Vet Res. 1989;50:1294-1296.
12. Hammermueller J, Kruth S, Prescott J, et al. Detection of toxin genes in Escherichia coli isolated from normal dogs and dogs with diarrhea. Can J Vet Res. 1995;59:265-270.
13. Gyles CL. Escherichia coli cytotoxins and enterotoxins. Can J Microbiol. 1992;38:734-746.
14. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998; 11: 450-479.
15. Gyles CL. Shiga toxin-producing Escherichia coli: An overview. J Anim Sci. 2007;85:E45-E62.
16. Beutin L, Geier D, Steinruck H, et al. Prevalence and some properties of verotoxin (Shiga-like toxin)-producing Escherichia coli in seven different species of healthy domestic animals. J Clin Microbiol. 1993;31:2483-2488.
17. Caprioli A, Morabito S, Brugère H, et al. Enterohaemorrhagic Escherichia coli: emerging issues on virulence and modes of transmission. Vet Res. 2005;36:289-311.
18. Bentancor A, Rumi MV, Gentilini MV, et al. Shiga toxin-producing and attaching effacing Escherichia coli in cats and dogs in a high hemolytic uremic syndrome incidence region in Argentina. FEMS Microbiol Lett. 2007;267:251-256.
19. Oliveira MG, Brito JRF, Carvalho RR, et al. Water buffaloes (Bubalus bubalis) identified as an important reservoir of Shiga toxin-producing Escherichia coli in Brazil. Appl Environ Microbiol. 2007;73:5945-5948.
20. Jay MT, Cooley M, Carychao D, et al. Escherichia coli O157:H7 in feral swine near spinach fields and cattle, central California coast. Emerg Infect Dis. 2007;13:1908-1911.
21. Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infec Dis. 1999;5:607-625.
22. O'Brien SJ, Adak GK, Gilham C. Contact with farming environment as a major risk factor for Shiga toxin (Verocytotoxin)-producing Escherichia coli O157 infection in humans. Emerg Infect Dis. 2001;7:1049-51.
23. Erickson MC, Doyle MP. Food as vehicle for transmission of Shiga toxin-producing Escherichia coli. J Food Prot. 2007;70:2426-2449.
24. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol. 2005;295:405-418.
25. Beutin L, Krause G, Zimmermann S, et al. Characterization of Shiga toxin-producing Escherichia coli strains isolated from human patients in Germany over a 3-year period. J Clin Microbiol. 2004;42:1099-1108.
26. Gerber A, Karch H, Allerberger F, et al. Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients,1997-2000, in Germany and Austria: a prospective study. J Infect Dis. 2002;186:493-500.
27. Elliott EJ, Robins-Browne RM, O'Loughlin EV, et al. Nationwide study of haemolytic uraemic syndrome: clinical, microbiological,and epidemiological features. Arch Dis Child. 2001;85:125-131.
28. Vaz TMI, Irino K, Kato MAMF, et al. Virulence properties and characteristics of Shiga toxin-producing Escherichia coli in São Paulo, Brazil, from 1976 through 1999. J Clin Microbiol. 2004;42:902-905.
29. Irino K, Vaz TMI, Medeiros MIC, et al. Serotype diversity as a drawback in the surveillance of Shiga toxin-producing Escherichia coli infections in Brazil. J Med Microbiol. 2007;56:565-567.
30. Bettelheim KA. The non-O157 Shiga-toxigenic (Verocytotoxigenic) Escherichia coli; under-rated pathogens. Critic Rev Microbiol. 2007;33:67-87.
31. Johnson KE, Thorpe CM, Sears CL. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. Clin Infec Dis. 2006;43:1587-95.
32. López EL, Prado V, O ́Ryan M, et al. Shigella and Shiga toxin-producing Escherichia coli causing bloody diarrhea in Latin America. Inf Dis Clin of North Am. 2000;14:41-65.
33. Prado V, Martínez J, Arellano C, et al. Variación temporal de genotipos y serogrupos de E. coli enterohemorrágicos aislados en niños chilenos con infecciones intestinales o síndrome hemolítico-urémico. Rev Med Chile. 1997;125:291-297.
34. González G, Pianciola L, Di Russo V, et al. Screening of Shiga toxin-producing Escherichia coli by PCR in patients with diarrhea in Neuquén City, Argentina. 7th International Symposium on Shiga Toxin (Verocytotoxin) - Producing Escherichia coli Infections. Buenos Aires: Argentina. 2009;May 10-13,p60.
35. Gianantonio C, Vitacco M, Mendilaharzu F, et al. The hemolytic uremic syndrome. J Pediatr. 1964;64:478-91.
36. Exeni R. Síndrome Urémico Hemolítico. Archivos Latinoamericanos de Nefrología Pediátrica. 2001;1:35-56.
37. Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic uremic syndrome. N Engl J Med. 1995;333:364-8.
38. Spizzirri FD, Rahman RC, Bibiloni N, et al. Childhood hemolytic uremic syndrome in Argentina: long term follow-up and prognostic features. Pediatr Nephrol. 1997;11:156-60.
39. Tarr P, Gordon C, Chandler W. Shiga-toxin producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073-86.
40. Cavagnaro F, Gana J, Lagomarsino E, et al. Síndrome hemolítico urémico. Experiencia de un centro pediátrico. Rev Med Chil. 2005;133:781-87
41. Ake J, Jelacic S, Ciol M, et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics. 2005;115:673-680.
42. Cordovéz A, Prado V, Maggi L, et al. Enterohemorrhagic Escherichia coli associated with hemolytic uremic syndrome in Chilean children. J Clin. Microbiol 1992;30:2153.
43. Michino H, Araki K, Minami S, et al. Massive outbreak of Escherichia coli O157:H7 infection in school chidren in Sakai city, Japan, associated with consumption of white radish sprouts. Am J Epidemiol. 1999;150:787-96.
44. Prado V, Cavagnaro F, et al. Síndrome hemolítico urémico asociado a infección intestinal por Escherichia coli productora de shiga toxina (STEC) en pacientes chilenos: aspectos clínicos y epidemiológicos. Rev Chil Infect. 2008;75:435-444
45. Rowe P, Orrbine E, Wells G, et al. Epidemiology of hemolytic-uremic syndrome in Canadian children from 1986 to 1988. J Pediatrics. 1991;119:218-24.
46. Rivas E, Miliwebsky E, Chinen I, et al. Epidemiología del síndrome hemolítico urémico en Argentina. Diagnóstico del agente etiológico, reservorios y vías de transmisión. Medicina. 2006;66:27-32.
47. Siegler R, Pavia A, Christofferson R, et al. A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. Pediatrics. 1994;94:35-40.
48. Ostroff SM, Neill MA, Lewis JH, et al. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O 157:H7 infections. J Infect Dis. 1989;160:994.
49. Large TM, Walk ST, Whittam TS. Variation in acid resistance among Shiga toxin-producing clones of pathogenic Escherichia coli. Appl. Environ Microbiol. 2005;71:2493-500.
50. Spears KJ, Roe AJ, Gally DL. A comparison of enteropathogenic and enterohemorrhagic Escherichia coli pathogenesis. FEMS Microbiol Lett. 2006;255:187-202.
51. McDaniel TK, Jarvis KG, Donnenberg MS, et al. A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proc Natl Acad Sci USA. 1995;92:1664-8.
52. Torres AG, Zhou X, Kaper JB. Adherence of diarrheagenic Escherichia coli strains to epithelial cells. Infect Immun. 2005;73:18-29.
53. Sandvig K, Spilsberg B, Lauvrak SU. Pathways followed by protein toxins into cells. Int J Med Microbiol. 2004;293:483-90.
54. Sandvig K, van Deurs B. Membrane traffic exploited by protein toxins. Annu Rev Cell Dev Biol. 2002;18:1-24.
55. Paton JC, Paton AW. Shiga toxin 'goes retro' in human primary kidney cells. Kidney Int. 2006;70:2049-51.
56. Kiarash A, Boyd B, Lingwood CA. Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosylceramide fatty acid homologues. J Biol Chem. 1994;269:11138-46.
57. Taneike I, Zhang HM, Wakisaka-Saito N, et al. Enterohemolysin operon of Shiga toxin-producing Escherichia coli: Avirulence function of inflammatory cytokine production from human monocytes. FEBS Lett. 2002;524:219-24.
58. Thorpe CM, Hurley BP, Lincicome LL, et al. Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells. Infect Immun. 1999;67:5985-93.
59. Yamasaki C, Natori Y, Zeng XT, et al. Induction of cytokines in a human colon epithelial cell line by Shiga toxin 1 (Stx1) and Stx2 but not by non-toxic mutant Stx1 which lacks N-glycosidase activity. FEBS Lett. 1999;442:231-4.
60. Hurley BP, Thorpe CM, Acheson DW. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun. 2001;69:6148-55.
61. Ray PE, Liu XH. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol. 2001;16:823-39.
62. Gianantonio CA, Vitacco M, Mendilaharzu F, et al. The hemolytic-uremic syndrome. Nephron. 1973;11:174-92.
63. Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int. 1995;48:2-19.
64. Creydt VP, Silberstein C, Zotta E, et al. Cytotoxic effect of Shiga toxin-2 holotoxin and its B subunit on human renal tubular epithelial cells. Microbes Infect. 2006;8:410-9.
65. Nestoridi E, Kushak RI, Duguerre D, et al. Upregulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin. Kidney Int. 2005;67:2254-2266.
66. O'Brien AD, Holmes RK. Shiga and Shiga-like toxins. Microbiol Rev. 1987;51:206-220.
67. Zhang W, Bielaszewska M, Kuczius T, et al. Identification, characterization, and distribution of a Shiga toxin 1 gene variant (stx1c) in Escherichia coli strains isolated from humans. J Clin Microbiol. 2002;40:1441-1446.
68. Friedrich AW, Borell J, Bielaszewska M, et al. Shiga toxin 1c-producing Escherichia coli strains: phenotypic and genetic characterization and association with human disease. J Clin Microbiol. 2003;41:2448-2453.
69. Kuczius T, Bielaszewska M, Friedrich A, et al. A rapid method for the discrimination of genes encoding classical Shiga toxin (Stx) 1 and its variants, Stx1c and Stx1d, in Escherichia coli. Mol Nutr Food Res. 2004;48:515-521.
70. Schmitt CK, McKee ML, O'Brien AD. Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511. Infect Immun. 1991;59:1065-1073.
71. Melton-Celsa AR, Darnell SC, O'Brien AD. Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice. Infect Immun. 1996;64:1569-1576.
72. Pierard D, Muyldermans G, Moriau L, et al. Identification of new verocytotoxin type 2 variant B-subunit genes in human and animal Escherichia coli isolates. J Clin Microbiol. 1998;36:3317-3322.
73. Weinstein DL, Jackson MP, Samuel JE, et al. Cloning and sequencing of a Shigalike toxin type II variant from Escherichia coli strain responsible for edema disease of swine. J Bacteriol. 1988;170:4223-4230.
74. Schmidt H, Scheef J, Morabito S, et al. A new Shiga toxin 2 variant (Stx2f) from Escherichia coli isolated from pigeons. Appl Environ Microbiol. 2000;66:1205-1208.
75. Morabito S, Dell'Omo G, Agrimi U, et al. Detection and characterization of Shiga toxin-producing Escherichia coli in feral pigeons. Vet Microbiol. 2001;82:275-283.
76. Leung PHM, Peiris JSM, Ng WWS, et al. A newly discovered verotoxin variant, VT2g, produced by bovine verocytotoxigenic Escherichia coli. Appl Environ Microbiol. 2003;69:7549-7553.
77. Kokai-Kun JF, Melton-Celsa AR, O'Brien AD. Elastase in intestinal mucus enhances the cytotoxicity of Shiga toxin type 2d. J Biol Chem. 2000;275:3713-3721.
78. Herold S, Karch H, Schmidt H. Shiga toxin encoding bacteriophages - genomes in motion. Int J Med Microbiol. 2004;294:115-121.
79. Schering J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol. 2008;23:1749:1760.
80. Friedrich AW, Bielaszewska M, Zhang W, et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis. 2002;185:74-84.
81. Grys TE, Siegel MB, Lathem WW, et al. The StcE protease contributes to intimate adherence of enterohemorrhagic Escherichia coli O157:H7 to host cells. Infect Immun. 2005;73:1295-303.
82. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat. Rev Microbiol. 2004;2:123-40.
83. Frankel G, Phillips AD, Rosenshine I, et al. Enteropathogenic and enterohaemorrhagic Escherichia coli: more subversive elements, Mol Microbiol. 1998;30:911-921.
84. Hartland EL, Batchelor M, Delahay RM, et al. Binding of intimin from enteropathogenic Escherichia coli to Tir and to host cells. Mol Microbiol. 1999;32:151-158.
85. Garrido P, Blanco M, Moreno-Paz M, et al. STEC-EPEC oligonucleotide microarray: A new tool for typing genetic variants of the LEE pathogenicity island of human and animal Shiga toxinproducing Escherichia coli (STEC) and enteropathogenic E. coli (EPEC) strains. J Clin Chem. 2006;52:192-201.
86. Blanco M, Blanco JE, Mora A, et al. Serotypes,virulence genes, and intimin types of Shiga toxin (verotoxin)-producing Escherichia coli isolates from cattle in Spain and identification of a new intimin variant gene (eae-xi). J Clin Microbiol. 2004;42:645-651.
87. Krause G, Zimmermann S, Beutin L. Investigation of domestic animals and pets as a reservoir for intimin-(eae) gene positive Escherichia coli types. Vet Microbiol. 2005;106:87-95.
88. Blanco M, Schumache S, Tasara T, et al. Serotypes, intimin variants and other virulence factors of eae positive Escherichia coli strains isolated from healthy cattle in Switzerland. Identification of a new intimin variant gene (eae-eta2). BMC Microbiol. 2005;5:23.
89. Rivas M, Miliwebsky E, Chinen I, et al. Characterization and epidemiologic subtyping of Shiga toxin-producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. Foodborne Pathog Dis. 2006;3:88-96.
90. Fitzhenry RJ, Pickard DJ, Hartland EL, et al. Intimin type influences the site of human intestinal mucosal colonisation by enterohaemorrhagic Escherichia coli O157:H7. Gut. 2002;50:180-185.
91. Ethelberg S, Olsen KE, Scheutz F, et al. Virulence factors for hemolytic uremic syndrome, Denmark. Emerg Infect Dis. 2004;10:845-7.
92. Dean-Nystrom EA, Gansheroff LJ, Mills M, et al. Vaccination of pregnant dams with intimin (O157) protects suckling piglets from Escherichia coli O157:H7 infection. Infect Immun. 2002;70:2414-8
93. Judge NA, Mason HS, O'Brien AD. Plant cell-based intimin vaccine given orally to mice primed with intimin reduces time of Escherichia coli O157:H7 shedding in feces. Infect Immun. 2004;72:168-75.
94. Potter AA, Klashinsky S, Li Y, et al. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine. 2004;22:362-9.
95. Karmali MA. Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome. Kidney Int Suppl. 2009;112:S4-7.
96. Coombes BK, Wickham ME, Mascarenhas M, et al. Molecular analysis as an aid to assess the public health risk of non-O157 Shiga toxin-producing Escherichia coli strains. Appl Environ Microbiol. 2008;74:2153-60.
97. Stevens MP, Timothy TS. Adhesins of Enterohemorrhagic Escherichia coli In: Kaper JB (ed) Escherichia coli and Salmonella: Cellular and Molecular Biology. ASM Press, Washington DC, 2005; Module 8.3.2.3
98. Karch H, Heesemann J, Laufs R, et al. A plasmid of enterohemorrhagic Escherichia coli O157:H7 is required for expression of a new fimbrial antigen and for adhesion to epithelial cells. Infect Immun. 1987;55:455-61
99. Fratamico PM, Bhaduri S, Buchanan RL. Studies on Escherichia coli serotype O157:H7 strains containing a 60-MDa plasmid and on 60-MDa plasmid-cured derivatives. J Med Microbiol. 1993;9:371-81.
100. Junkins AD, Doyle MP. Comparison of adherence properties of Escherichia coli O157:H7 and a 60-megadalton plasmidcured derivative. Curr Microbiol. 1989;19:21-7.
101. Toth I, Cohen ML, Rumschlag HS, et al. Influence of the 60-megadalton plasmid on adherence of Escherichia coli O157:H7 and genetic derivatives. Infect Immun. 1990;58:1223-31.
102. Tzipori S, Karch H, Wachsmuth IK, et al. Role of a 60-megadalton plasmid and Shiga-like toxins in the pathogenesis of infection caused by enterohemorrhagic Escherichia coli O157:H7 in gnotobiotic piglets. Infect. Immun. 1987;55:3117-25.
103. Sheng H, Lim JY, Knecht HJ, et al. Role of Escherichia coli O157:H7 virulence factors in colonization at the bovine terminal rectal mucosa. Infect Immun. 2006;74:4685-4693.
104. Dziva F, Mahajan A, Cameron P, et al. EspP, a typeV-secreted serine protease of enterohaemorrhagic Escherichia coli O157:H7, influences intestinal colonization of calves and adherence to bovine primary intestinal epithelial cells. FEMS Microbiol Lett. 2007;271:258-264.
105. Nicholls L, Grant TH, Robins-Browne RM. Identification of a novel genetic locus that is required for in vitro adhesion of a clinical isolate of enterohaemorrhagic Escherichia coli to epithelial cells. Mol Microbiol. 2000;35:275-288.
106. Stevens MP, Roe AJ, Vlisidou I, et al. Mutation of toxB and a truncated version of the efa1 gene in Escherichia coli O157:H7 influences the expression and secretion of locus of enterocyte effacement-encoded proteins but not intestinal colonization in calves or sheep. Infect Immun. 2004;72:5402-5411.
107. Hayashi T, Makino K, Ohnishi M, et al. Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. DNA Res. 2001;8:11-22.
108. Perna NT, Plunkett G, Burland V, et al. Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature. 2001;409:529-532.
109. Tatsuno I, Kimura H, Okutani A, et al. Isolation and characterization of mini-Tn5Km2 insertion mutants of enterohemorrhagic Escherichia coli O157:H7 deficient in adherence to Caco-2 cells. Infect Immun. 2000;68:5943-5952.
110. Tatsuno I, Horie M, Abe H, et al. toxB gene on pO157 of enterohemorrhagic Escherichia coli O157:H7 is required for full epithelial cell adherence phenotype. Infect Immun. 2001;69:6660-6669.
111. Tatarczak M, Wieczorek K, Posse B, et al. Identification of putative adhesin genes in Shiga toxigenic Escherichia coli isolated from different sources. Vet Microbiol. 2005;110:77-85.
112. Toma C, Martínez Espinosa E, Song T, et al. Distribution of putative adhesins in different seropathotypes of Shiga toxinproducing Escherichia coli. J Clin Microbiol. 2004;42:4937-4946.
113. Cergole-Novella MC, Nishimura LS, Santos LF, et al. Distribution of virulence profiles related to new toxin and putative adhesins in Shiga toxin-producing Escherichia coli isolated from diverse sources in Brazil. FEMS Microbiol Lett. 2007;274:329-334.
114. Vidal M, Escobar P, Prado V, et al. Distribution of putative adhesins in Shiga toxin-producing Escherichia coli (STEC) strains isolated from different sources in Chile. Epidemiol Infect. 2007;135:688-694.
115. Tarr PI, Bilge SS, Vary JC, et al. Iha: a novel Escherichia coli O157:H7 adherence-conferring molecule encoded on a recently acquired chromosomal island of conserved structure. Infect Immun. 2000;68:1400-1407.
116. Szalo IM, Goffaux F, Pirson V, et al. Presence in bovine enteropathogenic (EPEC) and enterohaemorrhagic (EHEC) Escherichia coli of genes encoding for putative adhesins of human EHEC strains. Res Microbiol. 2002;153:653-658.
117. Torres AG, Perna NT, Burland V, et al. Characterization of Cah, a calcium-binding and heat extractable autotransporter protein of enterohaemorrhagic Escherichia coli. Mol Microbiol. 2002;45:951-966.
118. Torres AG, Giron JA, Perna NT, et al. Identification and characterization of lpfABCCDE, a fimbrial operon of enterohemorrhagic Escherichia coli O157:H7. Infect Immun. 2002;70:5416-5427.
119. Torres AG, Kanack KJ, Tutt CB, et al. Characterization of the second long polar (LP) fimbriae of Escherichia coli O157:H7 and distribution of LP fimbriae in other pathogenic E. coli strains. FEMS Microbiol Lett. 2004;238:333-344.
120. Jordan DM, Cornick N, Torres AG, et al. Long polar fimbriae contribute to colonization by Escherichia coli O157:H7 in vivo. Infect Immun. 2004;72:6168-6171.
121. Torres AG, Milflores-Flores L, Garcia-Gallegos JG, et al. Environmental regulation and colonization attributes of the long polar fimbriae of Escherichia coli O157:H7. Int J Med Microbiol. 2007;297:177-185.
122. Dytoc MT, Ismaili A, Philpott DJ, et al. Distinct binding properties of eaeA-negative verocytotoxin-producing Escherichia coli of serotype O113:H21.Infect Immun. 1994;62:3494-3505.
123. Paton AW, Srimanote P, Woodrow MC, et al. Characterization of Saa, a novel autoagglutinating adhesin produced by locus of enterocyte effacement-negative Shiga-toxigenic Escherichia coli strains that are virulent for humans. Infect Immun. 2001;69:6999-7009.
124. Jenkins C, Perry NT, Cheasty T, et al. Distribution of the saa gene in strains of Shiga toxin-producing Escherichia coli of human and bovine origins. J Clin Microbiol. 2003;41:1775-1778.
125. Galli L, Miliwebsky E, Irino K, et al. Virulence profile comparison between LEE-negative Shiga toxin-producing Escherichia coli (STEC) strains isolated from cattle and humans. Vet Microbiol. 2010; (in press)
126. Vidal M, Prado V, Whitlock GC, et al. Subtractive hybridization and identification of putative adhesins in a Shiga toxinproducing eae-negative Escherichia coli. Microbiol. 2008;154:3639-3648.
127. Toma C, Nakasone N, Miliwebsky E, et al. Differential adherence of Shiga toxin-producing Escherichia coli harboring saa to epithelial cells. Int J Med Microbiol. 2008; doi: 10-1016/j.ijmm 2007.13003.
128. Doughty S, Sloan J, Bennett-Wood V, et al. Identification of a novel fimbrial gene cluster related to long polar fimbriae in locus of enterocyte effacement-negative strains of enterohemorrhagic Escherichia coli. Infect Immun 2002; 70: 6761-6769.
129. Osek J, Weiner M, Hartland EL. Prevalence of the lpfO113 gene cluster among Escherichia coli O157 isolates from different sources. Vet Microbiol. 2003;96:259-266.
130. Dos Santos LF, Irino K, Vaz TMI, et al. Set of virulence genes and genetic relatedness of O113:H21 Escherichia coli strains isolated from the animal reservoir and human infections in Brazil. J Med Microbiol. 2010;59:
131. Galli L, Torres AG, Rivas M. Identification of the Long Polar Fimbriae gene variants in Locus of Enterocyte Effacementnegative Shiga toxin-producing Escherichia coli strains isolated from humans and cattle in Argentina. FEMS Microbiol Lett. 2010b;(accepted)
132. Schmidt H, Maier E, Karch H, et al. Pore-forming properties of the plasmid-encoded hemolysin of enterohemorrhagic Escherichia coli O15:H7. Eur J Biochem. 1996;241:594-601.
133. Schmidt H, Beutin L, Karch H. Molecular analysis of the plasmid-encoded hemolysin of Escherichia coli O157:H7 strain EDL 933. Infect Immun. 1995;63:1055-1061.
134. Beutin L, Montenegro MA, Orskov I, et al. Close association of Verotoxin (Shiga-Like Toxin) production with enterohemolysin production in strains of Escherichia coli. J Clin Microbiol. 1989;27:2559-2564.
135. Janka A, Bielaszewska M, Dobrindt U, et al. Cytolethal distending toxin gene cluster in enterohemorrhagic Escherichia coli O157:H- and O157:H7: characterization and evolutionary considerations. Infect Immun. 2003;71:3634-3638.
136. Bielaszewska M, Fell M, Greune L, et al. Characterization of cytolethal distending toxin genes and expression in Shiga toxin-producing Escherichia coli strains of non-O157 serogroups. Infect Immun. 2004;72:1812-6.
137. Bielaszewska M, Sinha B, Kuczius T, et al. Cytolethal distending toxin from Shiga toxin-producing Escherichia coli O157 causes irreversible G2/M arrest, inhibition of proliferation and death of human endothelial cells. Infect Immun. 2005;73:552-562.
138. Paton AW, Srimanote P, Talbot UM, et al. A new family of potent AB(5) cytotoxins produced by Shiga toxigenic Escherichia coli. J Exp Med. 2004;200:35-46.
139. Osek, J. Identification of the subtilase cytotoxin gene among Shiga toxigenic Escherichia coli isolated from different sources. Bull Vet Inst Pulawy. 2006;50:29-33.
140. Khaitan A, Jandhyala DM, Thorpe CM, et al. The operon encoding SubAB, a novel cytotoxin, is present in Shiga toxinproducing Escherichia coli isolates from the United States. J Clin Microbiol. 2007;45:1374-1375.
141. Wolfson JJ, Jandhyala DM, Gorczyca LA, et al. Prevalence of the operon encoding subtilase cytotoxin in non-O157 Shiga toxin-producing Escherichia coli isolated from humans in the United States. J Clin Microbiol. 2009;47:3058-3059.
142. Irino K, Vieira MA, Gomes TAT, et al. Subtilase cytotoxin-encoding subAB operon found exclusively among Shiga toxinproducing Escherichia coli strains. J Clin Microbiol. 2010;48:988-990.
143. Berin MC, Darfeuille-Michaud A, Egan LJ, et al. Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF-kappaB and MAP kinase pathways and the upregulated expression of interleukin 8. Cel. Microbiol. 2002;4:635-48.
144. Miyamoto Y, Iimura M, Kaper JB, et al. Role of Shiga toxin versus H7 flagellin in enterohaemorrhagic Escherichia coli signalling of human colon epithelium in vivo. Cell Microbiol. 2006;8:869-79.
145. Brunder W, Schmidt H, Karch H. EspP, a novel extracellular serine protease of enterohemorrhagic Escherichia coli O157:H7 cleaves human coagulation factor V. Mol. Microbiol. 1997;24:767-778.
146. Brockmeyer J, Bielaszewska M, Fruth A, et al. Subtypes of the plasmid-encoded serine protease EspP in Shiga toxinproducing Escherichia coli: distribution, secretion, and proteolytic activity. Appl Environ Microbiol. 2007;73:6351-6359.
147. Louise CB, Obrig TG. Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Infect Immun. 1992;60:1536-43.
148. Keepers TR, Psotka MA, Gross LK, et al. A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J Am Soc Nephrol. 2006;17:3404-14.
149. Palermo M, Alves-Rosa F, Rubel C, et al. Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dosedependent opposite effects on Shiga toxin-2 lethality. Clin Exp Immunol. 2000;119:77-83.
150. Sauter KA, Melton-Celsa AR, Larkin K, et al. Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody. Infect Immun. 2008;76:4469-78.
151. Shultz PJ, Raij L. Endogenously synthesized nitric oxide prevents endotoxin induced glomerular thrombosis. J Clin Invest. 1992;90:1718-25.
152. Ray P, Acheson D, Chitrakar R, et al. Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2002;13:699-707.
153. Stahl AL, Svensson M, Morgelin M, et al. Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating latelets in patients with hemolytic uremic syndrome. Blood. 2006;108:167-76.
154. Karpman D, Papadopoulou D, Nilsson K, et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood. 2001;97: 3100-8.
155. Wagner PL, Acheson DW, Waldor MK. Human neutrophils and their products induce Shiga toxin production by enterohemorrhagic Escherichia coli. Infect Immun. 2001;69:1934-7.
156. Bielaszewska M, Karch H. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost 2005; 94: 312-8.
157. Chandler WL, Jelacic S, Boster DR, et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med. 2002;346:23-32.
158. Rangel JM, Sparling PH, Crowe C, et al. Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982-2002. Emerg Infect Dis. 2004;11:603-9.
159. Sartz L, De Jong B, Hjertqvist M, et al. An outbreak of Escherichia coli O157:H7 infection in southern Sweden associated with consumption of fermented sausage; aspects of sausage production that increase the risk of contamination. Epidemiol Infect. 2008;136:370-80.
160. Greenland K, de Jager C, Heuvelink A, et al. Nationwide outbreak of STEC O157 infection in the Netherlands, December 2008-January 2009: continuous risk of consuming raw beef products. Euro Surveill. 2008;14:19129.
161. Karmali MA, Mascarenhas M, Shen S, et al. Association of genomic O island 122 of Escherichia coli EDL 933 with verocytotoxin-producing Escherichia coli seropathotypes that are linked to epidemic and/or serious disease. J Clin Microbiol. 2003;41:4930-40.
162. Giraldi R, Guth BEC, Trabulsi LR. Production of Shiga-like toxin among Escherichia.coli strains and other bacteria isolated from diarrhea in São Paulo, Brazil. J Clin Microbiol. 1990;28:1460-1462.
163. Cantarelli V, Nagayama K, Takahashi A, et al. Isolation of Shiga toxin-producing Escherichia coli (STEC) serotype O91:H21 from a child with diarrhea in Porto Alegre city, RS, Brazil. Braz J Microbiol. 2000;31:266-70.
164. Guth BEC, Souza RL, Vaz TMI, et al. First Shiga Toxin-producing Escherichia coli isolate from a patient with hemolytic uremic syndrome, Brazil. Emerg Infect Dis. 2002;8:535-536.
165. Guth BEC, Vaz TMI, Gomes TAT, et al. Re-emergence of O103:H2 Shiga toxin-producing Escherichia coli infections in São Paulo, Brazil. J Med Microbiol. 2005;54:805-806.
166. De Toni F, Souza EM, Pedrosa FO, et al. A prospective study on Shiga toxin-producing Escherichia coli in children with diarrhoea in Paraná State, Brazil. Lett Appl Microbiol. 2009;48:645-647.
167. Souza RL, Nishimura LS, Guth BEC. Uncommon Shiga toxin-producing Escherichia coli serotype O165:HNM as cause of hemolytic uremic syndrome in São Paulo, Brazil. Diag Microbiol Infect Dis. 2007;59:223-225.
168. Irino K, Vaz TMI, Kato MAMF, et al. O157:H7 Shiga toxin-producing Escherichia coli strains associated with sporadic cases of diarrhea in São Paulo, Brazil. Emerg Infect Dis. 2002;8:446-447.
169. Bastos FC, Vaz TMI, Irino K, et al. Phenotypic characteristics, virulence profile and genetic relatedness of O157 Shiga toxin-producing Escherichia coli isolated in Brazil and other Latin American countries. FEMS Microbiol Lett. 2006;265:89-97.
170. Guth BEC, Souza RL, Andrade MC, et al. Hemolytic Uremic Syndrome in pediatrics care units in São Paulo, Brazil, from 2001 to 2005. 7th International Symposium on Shiga Toxin (Verocytotoxin) - Producing Escherichia coli Infections. Buenos Aires: Argentina. 2009;May 10-13,p54-55.
171. Olivares B, Araya P, Ibáñez D, et al. Genetic characterization of Chilean isolates of O157:H7 Shiga toxin producer Escherichia coli. 2003-2008. Public Health Institute of Chile. 7th International Symposium on Shiga Toxin (Verocytotoxin) - Producing Escherichia coli Infections. Buenos Aires: Argentina. 2009;May 10-13,p61.
172. Olivares B, Araya P, Prat S, et al. Laboratory surveillance system for STEC, Public Health Institute, ISP-Chile, 2007- September 2008. 7th International Symposium on Shiga Toxin (Verocytotoxin) - Producing Escherichia coli Infections. Buenos Aires: Argentina. 2009;May 10-13,p61.
173. Vidal RM, Valenzuela P, Corvalán L, et al. Serotype and virulence genes identification in Shiga toxin - producing Escherichia coli (STEC) isolated from pig and bovine at slaughter in Chile. 7th International Symposium on Shiga Toxin (Verocytotoxin) - Producing Escherichia coli Infections. Buenos Aires: Argentina. 2009;May 10-13,p76.
174. Gadea MDP, Varela G, Bernadá M, et al. Primer aislamiento en Uruguay de Escherichia coli productora de toxina Shiga del serotipo O157:H7 en una niña con síndrome urémico hemolítico. Rev Med Uruguay. 2004;20:79-81.
175. Varela G, Chinen I, Gadea P, et al. Detección y caracterización de Escherichia coli productor de toxina Shiga a partir de casos clínicos y de alimentos en Uruguay. Rev Arg Microbiol. 2008;40:93-100.
176. Gadea MDP, Balseiro V, González S, et al. Phenotypic and genotypic characterization of Shiga toxin - producing Escherichia coli strains isolated from animal in Uruguay. 7th International Symposium on Shiga Toxin (Verocytotoxin) - Producing Escherichia coli Infections. Buenos Aires: Argentina 2009; May 10-13,p.79.
177. Rivas M, Balbi L, Miliwebsky E, et al. Síndrome Urémico Hemolítico en niños de Mendoza, Argentina: su asociación con la infección por Escherichia coli productor de toxina Shiga. Medicina (Buenos Aires). 58:1-7,1998
178. Miliwebsky E, Balbi L, Gómez D, et al. Síndrome Urémico Hemolítico en niños de Argentina. Asociación con la infección por Escherichia coli productor de toxina Shiga. Bioquímica y Patología Clínica. 63:113-121,1999.
179. Gioffre A, Meichtri L, Miliwebsky E, et al. Detection of Shiga toxin-producing Escherichia coli in cattle in Argentina. Evaluation of two procedures. Vet Microbiol. 2002;87:301-3.
180. Meichtri L, Miliwebsky E, Gioffré A, et al. Shiga toxin-producing Escherichia coli in healthy young beef steers from Argentina: prevalence and virulence properties. I J Food Microbiol. 2004;96:189-198.
181. Leotta GA, Deza N, Origlia J, et al. Detection and characterization of Shiga toxin-producing Escherichia coli in captive wild mammals. Vet Microbiol. 2006;118:151-7.
182. Masana MO, Leotta GA, Del Castillo LL, et al. Prevalence, characterization, and genotypic analysis of Escherichia coli O157:H7/NM from selected beef exporting abattoirs of Argentina. J Food Protect. 2010;73:649-56.
183. Tanaro JD, Leotta GA, Lound LH, et al. Escherichia coli O157 in bovine feces and surface water streams in a beef cattle farm of Argentina.. Foodborne Path Dis. 2010;7:475-7.
184. Chinen I, Tanaro JD, Miliwebsky E, et al. Isolation and characterization of Escherichia coli O157:H7 from retails meats in Argentina. J Food Protect. 2001;64:1346-51.
185. Gómez D, Miliwebsky E, Fernández Pascua C, et al. Aislamiento y caracterización de Escherichia coli productor de toxina Shiga en hamburguesas supercongeladas y quesos de pasta blanda. Rev Arg Microbiol. 2002;34:66-71.
186. Rivas M, Caletti MG, Chinen I, et al. Home-prepared hamburger as the source for a sporadic case of hemolytic uremic syndrome, Argentina. Emerg Infect Dis. 2003;9:1184-6.
187. Oteiza JM, Chinen I, Miliwebsky E, et al. Isolation and characterization of Shiga toxin-producing Escherichia coli from precooked sausages (Morcillas). Food Microbiol. 2006;23:283-8.
188. Chinen I, Epsztein S, Melamed CL, et al. Shiga toxin-producing Escherichia coli O157 in beef and chicken burgers, and chicken carcasses in Buenos Aires, Argentina. I J Food Microbiol. 2009;132:167-71.
189. Almada G, Estrella P, Ottavianoni L, et al. Relación clonal de Escherichia coli O157:H7 aislada en un caso de SUH, un portador asintomático y muestras de alimentos. La Pampa, Argentina, 2008. Ind Cárn Latinoam. 2009;158:8-11.
190. Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000;342:1930-6.
191. Saldar N, Adnan S, Gangnon RE, et al. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis. JAMA. 2002;288:996-1001.
192. Oakes R, Siegler R, McReynolds M, et al. Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics. 2006;117:1656-62.
193. Trachtman H, Cnaan A, Christen E, et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated haemolytic uraemic syndrome in children. JAMA. 2003;290:1337-44.
194. Watanabe M, Matsuoka K, Kita E, et al. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. J Infect Dis. 2004;189:360-8.
195. Pinyon RA, Paton JC, Paton AW, et al. Refinement of a therapeutic Shiga toxin-binding probiotic for human trials. J Infect Dis. 2004;189:1547-55.
196. Silberstein C, Copeland DP, Chiang W-L, et al. A glucosylceramide synthase inhibitor prevents the cytotoxic effects of Shiga toxin-2 on human renal tubular epithelial cells. J Epith Biol Pharmacol. 2008;1:71-75.
197. Mukherjee J, Chios K, Fishwild D, et al. Human Stx2-specfic monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun. 2002;70:612-9.
198. Dowling TC, Chavaillaz PA, Young DG, et al. Phase I safety and pharmacological study of chimeric murine-human monoclonal antibody alpha Stx2 administered intravenously to healthy adult volunteers. Ant Agents and Chem. 2005;49:1808-1812.
199. McNelly TN, Mitchell MC, Roser T, et al. Immunization of cattle with a combination of purified intimin-531, EspA and Tir significantly reduces shedding of Escherichia coli O157:H7 following oral challenge.Vaccine. 2010;3:1422-1428.
200. Fox JT, Thomson DU, Drouillard JS, et al. Efficacy of Escherichia coli O157:H7 siderophore receptor/porin proteinsbased vaccine in feedlot cattle naturally shedding E. coli O157. Foodborne Pathog Dis. 2009;6:893-899.
201. Liu J, Sun Y, Zhu L, et al. Towards an attenuated enterohemorhagic Escherichia coli O157:H7 vaccine characterized by a deleted ler gene and containing apathogenic Shiga toxins. Vaccine. 2009;27:5929-5935.
202. Bentancor LV, Bilen M, Brando RJ, et al. A DNA vaccine encoding the enterohemorrhagic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model. Clin Vaccine Immunol. 2009;16:712-718.
203. Konadu EY, Parke JC, Jr, Trant TH, et al. Investigational vaccine for Escherichia coli O157: phase 1 study of O157 Ospecific polysaccharide-Pseudomonas aerugionsa recombinant exoprotein A conjugates in adults. J Infect Dis.1998;177:383-387.
204. Ahmed A, Li J, Shiloach Y, et al. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5 year-old children. J Infect Dis. 2006;193:512-21.